BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis

Background/Aims: The clinical relevance of the BRAF mutation in colorectal carcinoma (CRC) remains controversial. We performed a comprehensive meta-analysis to evaluate the precise relationship of BRAF mutation to clinicopathological features. Materials and Methods: A systematic search of the electronic databases, including PubMed, the Web of Knowledge, and the China Journal Net was performed between January 2005 and December 2015. Outcomes of interest included gender, tumor site, tumor differentiation, node involvement, tumor size, and AJCC stage. We calculated the pooled odds ratios (ORs) or risk ratios with 95% confidence intervals (CIs) for each study using a random or fixed-effect model. Results: Twenty-five studies with a total of 13208 patients were included. BRAF mutation-positive CRC patients were 1464 (11.1%). Our meta-analysis revealed that, in patients with CRC, the BRAF mutation was associated with female, proximal site, poor differentiation, >5 cm size, and advanced AJCC stage. Conclusions: This meta-analysis demonstrated that BRAF mutation was closely related to adverse pathological features and poor outcome of CRC.

[1]  W. Yi,et al.  KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients. , 2015, World journal of gastroenterology.

[2]  L. Memeo,et al.  KRAS and BRAF mutational status in colon cancer from Albanian patients , 2014, Diagnostic Pathology.

[3]  M. Ladanyi,et al.  BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.

[4]  M. Zhu,et al.  Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A meta‐analysis , 2013, Journal of digestive diseases.

[5]  K. Sheahan,et al.  BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. , 2013, Critical reviews in oncology/hematology.

[6]  D. Piscitelli,et al.  Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients , 2012, The International journal of biological markers.

[7]  L. Shen,et al.  [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases]. , 2012, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[8]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John D Potter,et al.  BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[10]  Albert C. Koong,et al.  BRAF-mutated, Microsatellite-stable Adenocarcinoma of the Proximal Colon: An Aggressive Adenocarcinoma With Poor Survival, Mucinous Differentiation, and Adverse Morphologic Features , 2012, The American journal of surgical pathology.

[11]  B. Das,et al.  Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma , 2012, The International journal of biological markers.

[12]  R. Jorissen,et al.  Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation , 2011, International journal of cancer.

[13]  Emma R Cantwell-Dorris,et al.  BRAFV600E: Implications for Carcinogenesis and Molecular Therapy , 2011, Molecular Cancer Therapeutics.

[14]  Y. Yatabe,et al.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer , 2011, British Journal of Cancer.

[15]  V. Lemmens,et al.  The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Terracciano,et al.  Clinicopathological and protein characterization of BRAF‐ and K‐RAS‐mutated colorectal cancer and implications for prognosis , 2010, International journal of cancer.

[17]  A. Russo,et al.  The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway , 2010, Oncology.

[18]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Elena A. Manilich,et al.  Divergent Oncogenic Changes Influence Survival Differences between Colon and Rectal Adenocarcinomas , 2009, Diseases of the colon and rectum.

[20]  B. Iacopetta,et al.  BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients. , 2009, Cancer letters.

[21]  D. English,et al.  Ethnicity and Risk for Colorectal Cancers Showing Somatic BRAF V600E Mutation or CpG Island Methylator Phenotype , 2008, Cancer Epidemiology Biomarkers & Prevention.

[22]  S. Kakar,et al.  Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. , 2008, European journal of cancer.

[23]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[24]  N. Cho,et al.  Clinicopathological features of CpG island methylator phenotype‐positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation , 2008, Pathology international.

[25]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[26]  K. Kawakami,et al.  BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status , 2006, Molecular Cancer.

[27]  M. Kasuga,et al.  BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms , 2005, International journal of cancer.

[28]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[29]  T. Kawabe,et al.  Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κB Pathway and Cellular Transformation , 2004, Cancer Research.

[30]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[31]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[32]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[33]  J. Sertić,et al.  Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. , 2012, Neoplasma (Bratislava).

[34]  J. Bond,et al.  Is BRAF Mutation Associated with Interval Colorectal Cancers? , 2010, Digestive Diseases and Sciences.

[35]  V. Mitev,et al.  Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer. , 2007, Cancer detection and prevention.

[36]  A. Terano,et al.  Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration. , 2007, Oncology reports.

[37]  池原 伸直.  BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms , 2006 .

[38]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.